ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
Estimated Pulse Wave Velocity Is Associated with Early Renal Impairment in Non-Diabetic Hypertensive Patients.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Estimated Pulse Wave Velocity Is Associated with Early Renal Impairment in Non-Diabetic Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hypertension is a major modifiable risk factor for chronic kidney disease (CKD), accelerating renal injury by promoting arterial stiffness. Estimated pulse wave velocity (ePWV), an indicator of arterial stiffness, is associated with CKD progression, but its relationship with urinary albumin-to-creatinine ratio (UACR) in non-diabetic hypertensive patients remains unclear. This retrospective study included 509 non-diabetic adults with essential hypertension. Participants were classified as having early renal impairment (UACR ≥30 mg/g, n = 167) or not (UACR <30 mg/g, n = 342). ePWV was calculated from age and mean blood pressure (MBP). The impairment group showed significantly higher ePWV (P < 0.001). Restricted cubic splines revealed a positive linear correlation between ePWV and UACR (P for nonlinear = 0.938). Multivariable logistic regression identified that ePWV was an independent risk factor for early renal impairment. Each 1 m/s increase in ePWV was associated with a 43.9% elevated risk of early renal impairment (OR = 1.439, 95% CI: 1.176-1.761), with the highest ePWV quartile (>9.70 m/s) showing an OR of 4.894 (95% CI: 2.019-11.86). ROC analysis showed that ePWV had the highest AUC at 0.710, higher than age (0.585) and MBP (0.693), and it provided greater incremental value for identifying early renal impairment than age and MBP when incorporated into the base model. Subgroup analyses by sex, age, BMI, and eGFR consistently supported these associations. In conclusion, ePWV is an independent risk marker for early renal impairment in non-diabetic hypertensive patients, supporting its potential use in early risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.